Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies, pressing for new ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

After privately vying for a change to Dynavax’s corporate strategy for months, life sciences investment firm Deep Track ...

Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement ...

JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...

Dynavax is currently conducting a randomized, active-controlled, dose escalation, multicenter Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to ...

During the last three months, 4 analysts shared their evaluations of Dynavax Technologies DVAX, revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...

Dynavax expects HEPLISAV-B product revenue in 2025 to range between $305 million and $325 million, representing a 17% year-over-year growth at the midpoint. The company anticipates achieving key ...